US6458772B1
(en)
|
1909-10-07 |
2002-10-01 |
Medivir Ab |
Prodrugs
|
US4374131A
(en)
*
|
1981-04-27 |
1983-02-15 |
E. R. Squibb & Sons, Inc. |
Amino and substituted amino phosphinyl-alkanoyl compounds
|
US4381297A
(en)
*
|
1981-05-04 |
1983-04-26 |
E. R. Squibb & Sons, Inc. |
Substituted carbonyl phosphinyl-alkanoyl compounds
|
US4416833A
(en)
*
|
1981-05-04 |
1983-11-22 |
E. R. Squibb & Sons, Inc. |
Substituted carbonyl phosphinyl-alkanoyl compounds
|
US4432971A
(en)
*
|
1981-08-03 |
1984-02-21 |
E. R. Squibb & Sons, Inc. |
Phosphonamidate compounds
|
US4432972A
(en)
*
|
1981-08-03 |
1984-02-21 |
E. R. Squibb & Sons, Inc. |
Phosphonamidate compounds
|
US4555506A
(en)
*
|
1981-12-24 |
1985-11-26 |
E. R. Squibb & Sons, Inc. |
Phosphorus containing compounds and use as hypotensives
|
US4452791A
(en)
*
|
1982-03-15 |
1984-06-05 |
E. R. Squibb & Sons, Inc. |
Aminoalkyl and related substituted phosphinic acid angiotensin converting enzyme inhibitors
|
US4560680A
(en)
*
|
1982-03-15 |
1985-12-24 |
E. R. Squibb & Sons, Inc. |
Aminoalkyl and related substituted phosphinic acid angiotensin converting enzyme inhibitors
|
US4448772A
(en)
*
|
1982-04-22 |
1984-05-15 |
E. R. Squibb & Sons, Inc. |
Phosphinylmethylaminocarbonyl imino acid compounds useful for treating hypertension
|
US4560681A
(en)
*
|
1982-04-22 |
1985-12-24 |
E. R. Squibb & Sons, Inc. |
Phosphinylmethylaminocarbonyl imino acid compounds useful for treating hypertension
|
US4681886A
(en)
*
|
1982-04-30 |
1987-07-21 |
E. R. Squibb & Sons, Inc. |
Substituted 4-phenoxy or 4-phenylthio prolines
|
CA1258853A
(en)
*
|
1982-04-30 |
1989-08-29 |
Rudiger D. Haugwitz |
Substituted 4-phenoxy prolines
|
US4427665A
(en)
*
|
1982-05-19 |
1984-01-24 |
E. R. Squibb & Sons, Inc. |
Phosphinylalkanoyl substituted imino acids and their use in hypotensive compositions
|
US4468519A
(en)
*
|
1982-06-14 |
1984-08-28 |
E. R. Squibb & Sons, Inc. |
Esters of phosphinylalkanoyl substituted prolines
|
US4703043A
(en)
*
|
1982-06-23 |
1987-10-27 |
E. R. Squibb & Sons, Inc. |
Phosphonyl hydroxyacyl amino acid derivatives as antihypertensive
|
US4616005A
(en)
*
|
1982-06-23 |
1986-10-07 |
E. R. Squibb & Sons, Inc. |
Phosphonyl hydroxyacyl amino acid derivatives as antihypertensives
|
US4452790A
(en)
*
|
1982-06-23 |
1984-06-05 |
E. R. Squibb & Sons, Inc. |
Phosphonyl hydroxyacyl amino acid derivatives as antihypertensives
|
US4442089A
(en)
*
|
1982-07-06 |
1984-04-10 |
E. R. Squibb & Sons, Inc. |
Method for treating glaucoma with topical or systemic ACE inhibitor compositions
|
US4444765A
(en)
*
|
1982-07-14 |
1984-04-24 |
E. R. Squibb & Sons, Inc. |
Amino and substituted amino phosphinylalkanoyl compounds useful for treating hypertension
|
US4567166A
(en)
*
|
1982-07-14 |
1986-01-28 |
E. R. Squibb & Sons, Inc. |
Amino and substituted amino phosphinylalkanoyl compounds useful for treating hypertension
|
US4470973A
(en)
*
|
1982-07-19 |
1984-09-11 |
E. R. Squibb & Sons, Inc. |
Substituted peptide compounds
|
US4621092A
(en)
*
|
1982-07-22 |
1986-11-04 |
E. R. Squibb & Sons, Inc. |
Substituted proline compounds, composition and method of use
|
US4742067A
(en)
*
|
1982-07-22 |
1988-05-03 |
E. R. Squibb & Sons, Inc. |
Acylalkylaminocarbonyl substituted amino and imino acid compounds
|
US4524212A
(en)
*
|
1982-09-27 |
1985-06-18 |
E. R. Squibb & Sons, Inc. |
Acyloxyketone substituted imino and amino acids
|
US4499079A
(en)
*
|
1982-11-18 |
1985-02-12 |
E. R. Squibb & Sons, Inc. |
Carboxy and substituted carboxy alkanoyl and cycloalkanoyl peptides
|
US4587234A
(en)
*
|
1982-11-18 |
1986-05-06 |
E. R. Squibb & Sons, Inc. |
Carboxy and substituted carboxy alkanoyl and cycloalkanoyl peptides
|
US4642315A
(en)
*
|
1982-11-18 |
1987-02-10 |
E. R. Squibb & Sons, Inc. |
Carboxy and substituted carboxy alkanoyl and cycloalkanoyl peptides
|
US4456595A
(en)
*
|
1982-12-06 |
1984-06-26 |
E. R. Squibb & Sons, Inc. |
Carboxy and substituted carboxy aroly peptides
|
US4555579A
(en)
*
|
1983-03-24 |
1985-11-26 |
E. R. Squibb & Sons, Inc. |
Dioxolenylmethyl ester prodrugs of phosphinic acid ace inhibitors
|
US4594199A
(en)
*
|
1983-09-19 |
1986-06-10 |
E. R. Squibb & Sons, Inc. |
Method for making phosphinic acid intermediates
|
US4602092A
(en)
*
|
1983-09-19 |
1986-07-22 |
E. R. Squibb & Sons, Inc. |
Method for making phosphinic acid intermediates
|
US4536501A
(en)
*
|
1984-03-30 |
1985-08-20 |
E. R. Squibb & Sons, Inc. |
Substituted 4-phenoxy or 4-phenylthio prolines
|
US4588819A
(en)
*
|
1984-11-19 |
1986-05-13 |
E. R. Squibb & Sons, Inc. |
Process and intermediates for preparing trans-4-substituted-s-prolines
|
US4625038A
(en)
*
|
1984-11-19 |
1986-11-25 |
E. R. Squibb & Sons, Inc. |
(25-trans)-4-substituted-2-pyrrolidines-methanols
|
US4634689A
(en)
*
|
1985-10-31 |
1987-01-06 |
Schering Corporation |
Phosphinylalkanoyl imino acids
|
US4738850A
(en)
*
|
1986-05-27 |
1988-04-19 |
E. R. Squibb & Sons, Inc. |
Controlled release formulation and method
|
US4734508A
(en)
*
|
1987-05-01 |
1988-03-29 |
E. R. Squibb & Sons, Inc. |
Process and intermediates for preparing 4-substituted proline derivatives
|
US4851514A
(en)
*
|
1987-05-01 |
1989-07-25 |
E. R. Squibb & Sons, Inc. |
Process for preparing a compound useful in preparing ace inhibitors and intermediate produced thereby
|
CA1333807C
(en)
*
|
1987-06-15 |
1995-01-03 |
David R. Kronenthal |
Process for preparing (trans)-4-phenyl-l-proline derivatives
|
US4931430A
(en)
*
|
1987-12-14 |
1990-06-05 |
E. R. Squibb & Sons, Inc. |
Method for preventing or treating anxiety employing an ACE inhibitor
|
US4937355A
(en)
*
|
1989-01-17 |
1990-06-26 |
E. R. Squibb & Sons, Inc. |
Process for preparing (trans)-4-substituted-dl-proline derivatives
|
US5093129A
(en)
*
|
1989-01-30 |
1992-03-03 |
E. R. Squibb & Sons, Inc. |
Method for treating addiction to a drug of abuse employing an ace inhibitor
|
US5008284A
(en)
*
|
1989-02-15 |
1991-04-16 |
E. R. Squibb & Sons, Inc. |
Method of reducing pre- and post-ischemic myocardial arrhythmias and fibrillation
|
US4931464A
(en)
*
|
1989-02-15 |
1990-06-05 |
E. R. Squibb & Sons, Inc. |
Method of reducing pre- and post-ischemic myocardial arrhythmias and fibrillation
|
US5006344A
(en)
*
|
1989-07-10 |
1991-04-09 |
E. R. Squibb & Sons, Inc. |
Fosinopril tablet formulations
|
DE3926606A1
(de)
*
|
1989-08-11 |
1991-02-14 |
Hoechst Ag |
Verfahren zur behandlung der cardialen sowie der vasculaeren hypertrophie und hyperplasie
|
US5227506A
(en)
*
|
1989-09-06 |
1993-07-13 |
Merck & Co., Inc. |
Acyloxymethyl esters of bisphosphonic acids as bone resorption inhibitors
|
US5212165A
(en)
*
|
1989-10-23 |
1993-05-18 |
E. R. Squibb & Sons, Inc. |
Method for rehabilitating the vasorelaxant action of the coronary arteries impaired through atherosclerosis or hypercholesterolemia employing an ace inhibitor
|
US5030648A
(en)
*
|
1990-01-12 |
1991-07-09 |
E. R. Squibb & Sons, Inc. |
Combination and method for treating obsessive-compulsive disorder, and motor and phonic tics in Tourettes' syndrome using such combination
|
US5008399A
(en)
*
|
1990-01-19 |
1991-04-16 |
E. R. Squibb & Sons, Inc. |
Diastereoselective preparation of phosphinate esters
|
US5162543A
(en)
*
|
1990-02-16 |
1992-11-10 |
E. R. Squibb & Sons, Inc. |
Selective processes for fosinopril polymorphs
|
US5166143A
(en)
*
|
1990-05-31 |
1992-11-24 |
E. R. Squibb & Sons, Inc. |
Method for preventing onset of restenosis after angioplasty employing an ace inhibitor
|
US5098889A
(en)
*
|
1990-09-17 |
1992-03-24 |
E. R. Squibb & Sons, Inc. |
Method for preventing or inhibiting loss of cognitive function employing a combination of an ace inhibitor and a drug that acts at serotonin receptors
|
US5032578A
(en)
*
|
1990-09-17 |
1991-07-16 |
E. R. Squibb & Sons, Inc. |
Method for preventing or treating depression employing a combination of an ace inhibitor and a drug that acts at serotonin receptors
|
US5157025A
(en)
*
|
1991-04-01 |
1992-10-20 |
E. R. Squibb & Sons, Inc. |
Method for lowering serum cholesterol employing a phosphorus containing ace inhibitor alone or in combination with a cholesterol lowering drug
|
US5977160A
(en)
*
|
1992-04-10 |
1999-11-02 |
Brigham And Women's Hospital, Inc. |
Methods for reducing risk of repeat myocardial infarction and increasing survival in heart attack victims
|
US5972990A
(en)
*
|
1992-04-10 |
1999-10-26 |
Brigham And Women's Hospital, Inc. |
Methods for reducing risk of repeat myocardial infarction and increasing survival in heart attack victims
|
US5504080A
(en)
*
|
1992-10-28 |
1996-04-02 |
Bristol-Myers Squibb Co. |
Benzo-fused lactams
|
US5508272A
(en)
*
|
1993-06-15 |
1996-04-16 |
Bristol-Myers Squibb Company |
Compounds containing a fused bicycle ring and processes therefor
|
DK0634175T3
(da)
*
|
1993-07-15 |
2001-04-30 |
Hoffmann La Roche |
Farmaceutisk kombination, der indeholder en hæmmer af renin-angiotensin-systemet og en endothelin-antagonist
|
US5362727A
(en)
*
|
1993-07-26 |
1994-11-08 |
Bristol-Myers Squibb |
Substituted azepino[2,1-a]isoquinoline compounds
|
US5525723A
(en)
*
|
1993-11-18 |
1996-06-11 |
Bristol-Myers Squibb Co. |
Compounds containing a fused multiple ring lactam
|
US5616775A
(en)
*
|
1994-05-05 |
1997-04-01 |
Bristol-Myers Squibb Co. |
Process for preparing homocystein analogs useful as intermediates for compounds containing a fused bicyclic ring
|
US6011021A
(en)
*
|
1996-06-17 |
2000-01-04 |
Guilford Pharmaceuticals Inc. |
Methods of cancer treatment using naaladase inhibitors
|
US5587375A
(en)
*
|
1995-02-17 |
1996-12-24 |
Bristol-Myers Squibb Company |
Azepinone compounds useful in the inhibition of ACE and NEP
|
US5877313A
(en)
|
1995-05-17 |
1999-03-02 |
Bristol-Myers Squibb |
Benzo-fused azepinone and piperidinone compounds useful in the inhibition of ACE and NEP
|
US5635504A
(en)
*
|
1995-06-07 |
1997-06-03 |
Bristol-Myers Squibb Co. |
Diazepine containing dual action inhibitors
|
US5650408A
(en)
*
|
1995-06-07 |
1997-07-22 |
Karanewsky; Donald S. |
Thiazolo benzazepine containing dual action inhibitors
|
US5795877A
(en)
*
|
1996-12-31 |
1998-08-18 |
Guilford Pharmaceuticals Inc. |
Inhibitors of NAALADase enzyme activity
|
US5977090A
(en)
*
|
1996-09-27 |
1999-11-02 |
Guilford Pharmaceuticals Inc. |
Pharmaceutical compositions and methods of treating compulsive disorders using NAALADase inhibitors
|
US6025344A
(en)
|
1996-06-17 |
2000-02-15 |
Guilford Pharmaceuticals Inc. |
Certain dioic acid derivatives useful as NAALADase inhibitors
|
US6046180A
(en)
*
|
1996-06-17 |
2000-04-04 |
Guilford Pharmaceuticals Inc. |
NAALADase inhibitors
|
US5672592A
(en)
*
|
1996-06-17 |
1997-09-30 |
Guilford Pharmaceuticals Inc. |
Certain phosphonomethyl-pentanedioic acid derivatives thereof
|
KR20000016750A
(ko)
|
1996-06-17 |
2000-03-25 |
토마스 씨. 서 |
Naaladase 억제를 이용한 암의 치료방법.
|
US5863536A
(en)
*
|
1996-12-31 |
1999-01-26 |
Guilford Pharmaceuticals Inc. |
Phosphoramidate derivatives
|
US6054444A
(en)
*
|
1997-04-24 |
2000-04-25 |
Guilford Pharmaceuticals Inc. |
Phosphonic acid derivatives
|
US6384022B1
(en)
|
1996-06-17 |
2002-05-07 |
Guilford Pharmaceuticals Inc. |
Prodrugs of NAALAdase inhibitors
|
US6025345A
(en)
*
|
1996-06-17 |
2000-02-15 |
Guilford Pharmaceuticals Inc. |
Inhibitors of NAALADase enzyme activity
|
US5902817A
(en)
*
|
1997-04-09 |
1999-05-11 |
Guilford Pharmaceuticals Inc. |
Certain sulfoxide and sulfone derivatives
|
US6071965A
(en)
*
|
1996-06-17 |
2000-06-06 |
Guilford Pharmaceuticals Inc. |
Phosphinic alkanoic acid derivatives
|
US5962521A
(en)
|
1997-04-04 |
1999-10-05 |
Guilford Pharmaceuticals Inc. |
Hydroxamic acid derivatives
|
US5981209A
(en)
*
|
1997-12-04 |
1999-11-09 |
Guilford Pharmaceuticals Inc. |
Use of NAALADase activity to identify prostate cancer and benign prostatic hyperplasia
|
US6028216A
(en)
*
|
1997-12-31 |
2000-02-22 |
Guilford Pharmaceuticals Inc. |
Asymmetric syntheses and intermediates for preparing enantiomer-enriched hydroxyphosphinyl derivatives
|
US20020128301A1
(en)
*
|
1998-02-13 |
2002-09-12 |
Medivir AB |
Non-nucleoside reverse transcriptase inhibitors
|
US6121252A
(en)
*
|
1998-03-30 |
2000-09-19 |
Guilford Pharmaceuticals Inc. |
Phosphinic acid derivatives
|
FR2777780B1
(fr)
|
1998-04-22 |
2001-05-04 |
Inst Nat Sante Rech Med |
Derives d'(alpha-aminophosphino) peptides, leur procede de preparation et les compositions qui les contiennent
|
CZ200113A3
(cs)
|
1998-07-06 |
2001-08-15 |
Guilford Pharmaceuticals Inc. |
Inhibitory NAALAdázy využitelné jako léčiva a farmaceutické kompozice, které je obsahují
|
US6395718B1
(en)
*
|
1998-07-06 |
2002-05-28 |
Guilford Pharmaceuticals Inc. |
Pharmaceutical compositions and methods of inhibiting angiogenesis using naaladase inhibitors
|
US6265609B1
(en)
|
1998-07-06 |
2001-07-24 |
Guilford Pharmaceuticals Inc. |
Thio-substituted pentanedioic acid derivatives
|
US6313159B1
(en)
|
1999-08-20 |
2001-11-06 |
Guilford Pharmaceuticals Inc. |
Metabotropic glutamate receptor ligand derivatives as naaladase inhibitors
|
AU3885901A
(en)
*
|
1999-09-21 |
2001-04-24 |
Emory University |
Methods and compositions for treating platelet-related disorders
|
US20030113330A1
(en)
*
|
1999-11-08 |
2003-06-19 |
Uhal Bruce D. |
Methods for treating pulmonary fibrosis
|
DE60138535D1
(de)
*
|
2000-02-04 |
2009-06-10 |
Children S Hospital Res Founda |
Verwendung von lysosomal acid lipase zur behandlung von atherosklerose und ähnlichen krankheiten
|
CA2427271A1
(en)
|
2000-12-14 |
2002-06-20 |
Brigham And Women's Hospital, Inc. |
Inflammatory markers for detection and prevention of diabetes mellitus
|
CA2330904C
(en)
|
2001-01-11 |
2006-10-24 |
Bernard Charles Sherman |
Fosinopril sodium tablet formulation
|
JP2004520440A
(ja)
*
|
2001-04-30 |
2004-07-08 |
ルピン ラボラトリーズ リミティド |
フォシノプリルナトリウムの製造方法
|
EP1443919A4
(en)
*
|
2001-11-16 |
2006-03-22 |
Bristol Myers Squibb Co |
DOUBLE INHIBITORS OF THE FATTY ACID BINDING PROTEIN OF THE ADIPOCYTES AND THE FATTY ACID BINDING PROTEIN OF KERATINOCYTES
|
IL163666A0
(en)
|
2002-02-22 |
2005-12-18 |
New River Pharmaceuticals Inc |
Active agent delivery systems and methods for protecting and administering active agents
|
IS1935B
(is)
*
|
2002-03-19 |
2004-06-16 |
Actavis Group Hf. |
Fósínópríl lyfjasamsetning
|
JP4514606B2
(ja)
|
2002-05-09 |
2010-07-28 |
ザ ブライハム アンド ウイメンズ ホスピタル, インコーポレイテッド |
心血管疾患マーカーおよび治療標的としてのil1rl−1
|
US7105539B2
(en)
*
|
2002-12-03 |
2006-09-12 |
Enobia Pharma |
Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of phex
|
US20040110241A1
(en)
*
|
2002-12-06 |
2004-06-10 |
Segal Mark S. |
Materials and methods for monitoring vascular endothelial function
|
JP2006521287A
(ja)
|
2002-12-20 |
2006-09-21 |
エスティ.ジェイムス アソシエイト エルエルシー/フェイバー リサーチ シリーズ |
医薬製剤用の高圧圧縮
|
CL2004000366A1
(es)
*
|
2003-02-26 |
2005-01-07 |
Pharmacia Corp Sa Organizada B |
USO DE UNA COMBINACION DE UN COMPUESTO DERIVADO DE PIRAZOL INHIBIDOR DE QUINASA p38, Y UN INHIBIDOR DE ACE PARA TRATAR DISFUNCION RENAL, ENFERMEDAD CARDIOVASCULAR Y VASCULAR, RETINOPATIA, NEUROPATIA, EDEMA, DISFUNCION ENDOTELIAL O INSULINOPATIA.
|
CL2004000544A1
(es)
*
|
2003-03-18 |
2005-01-28 |
Pharmacia Corp Sa Organizada B |
Uso de una combinacion farmaceutica, de un antagonista del receptor de aldosterona y un inhibidor de endopeptidasa neutral, util para el tratamiento y prevencion de una condicion patologica relacionada con hipertension, disfuncion renal, insulinopati
|
NZ543741A
(en)
*
|
2003-05-30 |
2009-10-30 |
Ranbaxy Lab Ltd |
Substituted pyrrole derivatives and their use as HMG-Co inhibitors
|
US7459474B2
(en)
*
|
2003-06-11 |
2008-12-02 |
Bristol-Myers Squibb Company |
Modulators of the glucocorticoid receptor and method
|
US20050037063A1
(en)
*
|
2003-07-21 |
2005-02-17 |
Bolton Anthony E. |
Combined therapies
|
EP1663184A2
(en)
|
2003-08-29 |
2006-06-07 |
The Brigham And Women's Hospital, Inc. |
Hydantoin derivatives as inhibitors of cellular necrosis
|
US7371759B2
(en)
*
|
2003-09-25 |
2008-05-13 |
Bristol-Myers Squibb Company |
HMG-CoA reductase inhibitors and method
|
US7420059B2
(en)
*
|
2003-11-20 |
2008-09-02 |
Bristol-Myers Squibb Company |
HMG-CoA reductase inhibitors and method
|
EP2306192B1
(en)
|
2003-12-05 |
2015-10-14 |
The Cleveland Clinic Foundation |
Risk Markers For Cardiovascular Disease
|
US7803838B2
(en)
*
|
2004-06-04 |
2010-09-28 |
Forest Laboratories Holdings Limited |
Compositions comprising nebivolol
|
EP2927693A1
(en)
|
2004-10-06 |
2015-10-07 |
The Brigham and Women's Hospital |
Relevance of achieved levels of markers of systemic inflammation following treatment
|
KR20080016527A
(ko)
*
|
2005-01-31 |
2008-02-21 |
밀란 래보러토리즈, 인크. |
하이드록시화된 네비볼롤을 함유하는 약학적 조성물
|
NZ563759A
(en)
|
2005-05-31 |
2010-06-25 |
Mylan Lab Inc |
Compositions comprising nebivolol, a hydralazine compound and an isosorbide nitrate
|
WO2007030375A2
(en)
*
|
2005-09-08 |
2007-03-15 |
Children's Hospital Medical Center |
Lysosomal acid lipase therapy for nafld and related diseases
|
US8119358B2
(en)
|
2005-10-11 |
2012-02-21 |
Tethys Bioscience, Inc. |
Diabetes-related biomarkers and methods of use thereof
|
US7741317B2
(en)
|
2005-10-21 |
2010-06-22 |
Bristol-Myers Squibb Company |
LXR modulators
|
CA2627599A1
(en)
*
|
2005-11-08 |
2007-05-18 |
Ranbaxy Laboratories Limited |
Process for (3r,5r)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(4-hydroxy methyl phenyl amino)carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid hemi calcium salt
|
US7888376B2
(en)
|
2005-11-23 |
2011-02-15 |
Bristol-Myers Squibb Company |
Heterocyclic CETP inhibitors
|
US7592461B2
(en)
|
2005-12-21 |
2009-09-22 |
Bristol-Myers Squibb Company |
Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
|
AR059838A1
(es)
*
|
2006-03-14 |
2008-04-30 |
Ranbaxy Lab Ltd |
Formulaciones para dosis estabilizantes de estatina
|
CA2646598C
(en)
*
|
2006-03-21 |
2014-08-19 |
Amylin Pharmaceuticals, Inc. |
Peptide-peptidase inhibitor conjugates and methods of using same
|
US20070238770A1
(en)
*
|
2006-04-05 |
2007-10-11 |
Bristol-Myers Squibb Company |
Process for preparing novel crystalline forms of peliglitazar, novel stable forms produced therein and formulations
|
US7858611B2
(en)
*
|
2006-05-09 |
2010-12-28 |
Braincells Inc. |
Neurogenesis by modulating angiotensin
|
EP2377531A2
(en)
|
2006-05-09 |
2011-10-19 |
Braincells, Inc. |
Neurogenesis by modulating angiotensin
|
WO2007146229A2
(en)
*
|
2006-06-07 |
2007-12-21 |
Tethys Bioscience, Inc. |
Markers associated with arteriovascular events and methods of use thereof
|
CL2007002044A1
(es)
*
|
2006-07-14 |
2008-06-13 |
Ranbaxy Lab Ltd |
Polimorfo cristalino de la sal hemicalcica del acido (3r,5r)-7-[2-(4-fluorofenil)-5-isopropil-3-fenil-4-[(4-hidroximetilfenilamino)carbonil]-pirrol-1-il]-3,5-dihidroxiheptanoico; composicion farmaceutica; y uso para el tratamiento de la diabetes, enf
|
US8198311B2
(en)
|
2006-11-01 |
2012-06-12 |
Bristol-Myers Squibb Company |
Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
|
EP2089355A2
(en)
|
2006-11-01 |
2009-08-19 |
Brystol-Myers Squibb Company |
Modulators of glucocorticoid receptor, ap-1, and/or nf- kappa b activity and use thereof
|
EP2094643B1
(en)
|
2006-12-01 |
2012-02-29 |
Bristol-Myers Squibb Company |
N-((3-benzyl)-2,2-(bis-phenyl)-propan-1-amine derivatives as cetp inhibitors for the treatment of atherosclerosis and cardiovascular diseases
|
CA2684308A1
(en)
|
2007-04-18 |
2008-10-30 |
Tethys Bioscience, Inc. |
Diabetes-related biomarkers and methods of use thereof
|
US8969514B2
(en)
|
2007-06-04 |
2015-03-03 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
|
MX354786B
(es)
|
2007-06-04 |
2018-03-21 |
Synergy Pharmaceuticals Inc |
Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos.
|
EP2195034A2
(en)
*
|
2007-09-27 |
2010-06-16 |
Amylin Pharmaceuticals, Inc. |
Peptide-peptidase inhibitor conjugates and methods of making and using same
|
US7828840B2
(en)
*
|
2007-11-15 |
2010-11-09 |
Med Institute, Inc. |
Medical devices and methods for local delivery of angiotensin II type 2 receptor antagonists
|
ES2627848T3
(es)
|
2008-06-04 |
2017-07-31 |
Synergy Pharmaceuticals Inc. |
Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
|
GB2462022B
(en)
*
|
2008-06-16 |
2011-05-25 |
Biovascular Inc |
Controlled release compositions of agents that reduce circulating levels of platelets and methods thereof
|
ES2624828T3
(es)
|
2008-07-16 |
2017-07-17 |
Synergy Pharmaceuticals Inc. |
Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
|
JP5619756B2
(ja)
*
|
2008-11-05 |
2014-11-05 |
クラリアント・ファイナンス・(ビーブイアイ)・リミテッド |
アルキルアルコール/アクロレインを使用したジアルキルホスフィン酸、−エステル及び−塩の製造方法及びそれらの使用
|
DE102008055914A1
(de)
*
|
2008-11-05 |
2010-05-06 |
Clariant International Limited |
Verfahren zur Herstellung von mono-hydroxyfunktionalisierten Dialkylphosphinsäuren, -estern und -salzen mittels Acroleinen und ihre Verwendung
|
DE102008055916A1
(de)
*
|
2008-11-05 |
2010-05-06 |
Clariant International Limited |
Verfahren zur Herstellung von mono-hydroxyfunktionalisierten Dialkylphosphinsäuren, -estern und -salzen mittels Allylalkoholen und ihre Verwendung
|
DE102008056342A1
(de)
*
|
2008-11-07 |
2010-05-12 |
Clariant International Limited |
Verfahren zur Herstellung von Dialkylphosphinsäuren, -estern und -salzen mittels Acrylnitrilen und ihre Verwendung
|
EP2352740B1
(de)
*
|
2008-11-07 |
2014-09-24 |
Clariant Finance (BVI) Limited |
Verfahren zur herstellung von dialkylphosphinsäuren, -estern und -salzen mittels acrylsäurederivaten und ihre verwendung
|
DE102008056341A1
(de)
*
|
2008-11-07 |
2010-05-12 |
Clariant International Limited |
Verfahren zur Herstellung von monoaminofunktionalisierten Dialkylphosphinsäuren, -estern und -salzen mittels Acrylnitrilen und ihre Verwendung
|
DE102008056339A1
(de)
*
|
2008-11-07 |
2010-05-12 |
Clariant International Limited |
Verfahren zur Herstellung von mono-aminofunktionalisierten Dialkylphosphinsäuren, -estern und -salzen und ihre Verwendung
|
US8772519B2
(en)
|
2008-11-11 |
2014-07-08 |
Clariant Finance (Bvi) Limited |
Process for preparing mono-allyl-functionalized dialkylphosphinic acids, salts and esters thereof with allylic compounds, and the use thereof
|
DE102008060036A1
(de)
*
|
2008-12-02 |
2010-06-10 |
Clariant International Limited |
Verfahren zur Herstellung von mono-carboxyfunktionalisierten Dialkylphosphinsäuren, -estern und -salzen mittels Vinylester einer Carbonsäure und ihre Verwendung
|
DE102008060035A1
(de)
*
|
2008-12-02 |
2010-06-10 |
Clariant International Limited |
Verfahren zur Herstellung von mono-hydroxyfunktionalisierten Dialkylphosphinsäuren, -estern und -salzen mittels Vinylester einer Carbonsäure und ihre Verwendung
|
DE102008060535A1
(de)
*
|
2008-12-04 |
2010-06-10 |
Clariant International Limited |
Verfahren zur Herstellung von mono-carboxyfunktionalisierten Dialkylphosphinsäuren, -estern und -salzen mittels Vinylether und ihre Verwendung
|
US9181487B2
(en)
|
2008-12-18 |
2015-11-10 |
Clariant Finance (Bvi) Limited |
Process for preparing ethylenedialkylphosphinic acids, esters and salts by means of acetylene and use thereof
|
DE102008063642A1
(de)
|
2008-12-18 |
2010-06-24 |
Clariant International Limited |
Verfahren zur Herstellung von monocarboxyfunktionalisierten Dialkylphosphinsäuren, -estern und -salzen mittels Alkylenoxiden und ihre Verwendung
|
DE102008063627A1
(de)
|
2008-12-18 |
2010-06-24 |
Clariant International Limited |
Verfahren zur Herstellung von monohydroxyfunktionalisierten Dialkylphosphinsäuren,-estern und -salzen mittels Ethylenoxid und ihre Verwendung
|
DE102008063668A1
(de)
|
2008-12-18 |
2010-07-01 |
Clariant International Limited |
Verfahren zur Herstellung von Alkylphosponsäuren, -estern und -salzen mittels Oxidation von Alkylphosphonigsäuren und ihre Verwendung
|
DE102008064012A1
(de)
|
2008-12-19 |
2010-06-24 |
Clariant International Limited |
Halogenfreie Addukte von Alkylphosphonigsäurederivaten und diesterbildenden Olefinen, halogenfreie Verfahren zu deren Herstellung und ihre Verwendung
|
DE102008064003A1
(de)
|
2008-12-19 |
2010-06-24 |
Clariant International Limited |
Verfahren zur Herstellung von mono-funktionalisierten Dialkylphosphinsäuren, -estern und -salzen und ihre Verwendung
|
CN101445475B
(zh)
*
|
2008-12-30 |
2010-12-22 |
浙江工业大学 |
一种(反)-4-环己基-l-脯氨酸的制备方法
|
IT1394407B1
(it)
|
2009-05-25 |
2012-06-15 |
Dipharma Francis Srl |
Procedimento per la preparazione di fosinopril e suoi intermedi
|
AU2011210508B2
(en)
|
2010-02-01 |
2015-01-29 |
The Hospital For Sick Children |
Remote ischemic conditioning for treatment and prevention of restenosis
|
JP2013523240A
(ja)
|
2010-03-31 |
2013-06-17 |
ザ・ホスピタル・フォー・シック・チルドレン |
心筋梗塞後の結果を改善するための遠隔虚血コンディショニングの使用
|
WO2011127341A2
(en)
|
2010-04-08 |
2011-10-13 |
The Hospital For Sick Children |
Use of remote ischemic conditioning for traumatic injury
|
US9616097B2
(en)
|
2010-09-15 |
2017-04-11 |
Synergy Pharmaceuticals, Inc. |
Formulations of guanylate cyclase C agonists and methods of use
|
IT1406151B1
(it)
|
2010-12-06 |
2014-02-14 |
Dipharma Francis Srl |
Procedimento per la preparazione di fosinopril e suoi intermedi
|
DK2734222T3
(en)
|
2011-07-18 |
2017-01-30 |
Critical Care Diagnostics Inc |
PROCEDURES FOR TREATING CARDIOVASCULAR DISEASES AND PREDICTING THE EFFECTIVENESS OF MOTION THERAPY
|
KR101708538B1
(ko)
|
2011-08-26 |
2017-02-20 |
욱크하르트 리미티드 |
심혈관 질환의 치료 방법
|
EP2855458B1
(en)
|
2012-05-11 |
2018-08-08 |
Reset Therapeutics, Inc. |
Carbazole-containing sulfonamides as cryptochrome modulators
|
ES2786506T3
(es)
|
2012-08-01 |
2020-10-13 |
Zahra Tavakoli |
Composiciones congeladas fluidas que comprenden un agente terapéutico
|
US9486494B2
(en)
|
2013-03-15 |
2016-11-08 |
Synergy Pharmaceuticals, Inc. |
Compositions useful for the treatment of gastrointestinal disorders
|
US9725452B2
(en)
|
2013-03-15 |
2017-08-08 |
Presidents And Fellows Of Harvard College |
Substituted indoles and pyrroles as RIP kinase inhibitors
|
EP2970384A1
(en)
|
2013-03-15 |
2016-01-20 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase and their uses
|
EP3981388A1
(en)
|
2013-03-21 |
2022-04-13 |
Eupraxia Pharmaceuticals USA LLC |
Injectable sustained release composition and method of using the same for treating inflammation in joints and pain associated therewith
|
WO2014170786A1
(en)
|
2013-04-17 |
2014-10-23 |
Pfizer Inc. |
N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases
|
KR102272746B1
(ko)
|
2013-06-05 |
2021-07-08 |
보슈 헬스 아일랜드 리미티드 |
구아닐레이트 사이클라제 c의 초순수 작용제, 및 이의 제조 및 사용 방법
|
US9593113B2
(en)
|
2013-08-22 |
2017-03-14 |
Bristol-Myers Squibb Company |
Imide and acylurea derivatives as modulators of the glucocorticoid receptor
|
TWI690521B
(zh)
|
2014-04-07 |
2020-04-11 |
美商同步製藥公司 |
作為隱花色素調節劑之含有咔唑之醯胺類、胺基甲酸酯類及脲類
|
WO2016055901A1
(en)
|
2014-10-08 |
2016-04-14 |
Pfizer Inc. |
Substituted amide compounds
|
PT3206672T
(pt)
|
2015-10-27 |
2018-06-20 |
Eupraxia Pharmaceuticals Inc |
Formulações de libertação prolongada de anestésicos locais
|
WO2020150473A2
(en)
|
2019-01-18 |
2020-07-23 |
Dogma Therapeutics, Inc. |
Pcsk9 inhibitors and methods of use thereof
|
CN111196776B
(zh)
*
|
2019-11-09 |
2022-11-04 |
上海大学 |
氰基亚胺取代芘类衍生物及其合成方法
|